Video
Dr. Dandoy on TMA Risk After Pediatric Allogeneic Stem Cell Transplant
Author(s):
Christopher E. Dandoy, MD, MSc, says that patients undergoing allogenic stem cell transplant are at high-risk of developing thrombotic microangiopathy.
Christopher E. Dandoy, MD, MSc, assistant professor of pediatrics at Cincinnati Children’s Hospital, says that patients undergoing allogeneic stem cell transplant are at high-risk of developing thrombotic microangiopathy (TMA).
TMA occurs in 30% of these patients and can occur as early as 7 days after transplant. When it is identified to be present, the patient can be properly treated right away, Dandoy notes.
Tools from these data presented at the 2019 Transplantation & Cellular Therapy Meetings as well as tools from other data can be used to identify these patients even earlier.
